Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy
Laura Schäkel(University of Bonn), Christa E. Müller(University of Bonn), Salahuddin Mirza(University of Bonn), Jean Sévigny(Université Laval), Riekje Winzer(Universität Hamburg), Riham M. Idris(University of Bonn), Haneen Al-Hroub(University of Bonn), Julie Pelletier(Université Laval), Vittoria Lopez(University of Bonn), Eva Tolosa(Universität Hamburg)
Cited by 34
Related Papers
The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance
|Purinergic Signalling|2006|928
Identification and Characterization of CD39/Vascular ATP Diphosphohydrolase
|Journal of Biological Chemistry|1996|586
Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation
|Nature Medicine|1999|575
Carbon Monoxide Generated by Heme Oxygenase-1 Suppresses the Rejection of Mouse-to-Rat Cardiac Transplants
|The Journal of Immunology|2001|462
Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8
|Purinergic Signalling|2005|336